M&A / Deals Lilly enters psychedelic realm through $2.8bn AtaiBeckley takeover Pharmaceutical TechnologyThis acquisition marks Eli Lilly's first move into the psychedelic space as the pharma curates a diversified pipeline.NeuroscienceRead full story pharminent July 16, 2026 (Last updated: July 17, 2026) Pharmaceutical Technology This acquisition marks Eli Lilly’s first move into the psychedelic space as the pharma curates a diversified pipeline. Neuroscience Read full story Post navigation Previous: Merck dives into cholesterol with first FDA approval for oral PCSK9 inhibitorNext: FDA Approves At-Home Leqembi for Early Alzheimer’s Disease Related Stories M&A / Deals Exegenesis Bio and Modalis sign research deal for Duchenne therapy pharminent September 11, 2026 M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026